BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19228809)

  • 1. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Diabetes; 2009 Mar; 58(3):745-9. PubMed ID: 19228809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients.
    He R; Zhang D; Lu W; Zheng T; Wan L; Liu F; Jia W
    Diabetes Res Clin Pract; 2015 Jul; 109(1):57-63. PubMed ID: 26004431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
    Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
    Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment.
    Cho SK; Chung JY
    Int J Clin Pharmacol Ther; 2016 Apr; 54(4):253-62. PubMed ID: 26784938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacogenomics J; 2009 Aug; 9(4):242-7. PubMed ID: 19381165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression.
    Kalamajski S; Huang M; Dalla-Riva J; Keller M; Dawed AY; Hansson O; Pearson ER; ; Mulder H; Franks PW
    Hum Mol Genet; 2022 Feb; 31(4):491-498. PubMed ID: 34505146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
    Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
    Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.
    Meyer zu Schwabedissen HE; Verstuyft C; Kroemer HK; Becquemont L; Kim RB
    Am J Physiol Renal Physiol; 2010 Apr; 298(4):F997-F1005. PubMed ID: 20053795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
    Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
    J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin.
    Christensen MM; Pedersen RS; Stage TB; Brasch-Andersen C; Nielsen F; Damkier P; Beck-Nielsen H; Brøsen K
    Pharmacogenet Genomics; 2013 Oct; 23(10):526-34. PubMed ID: 23873119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
    Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
    Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of
    Chen P; Cao Y; Chen S; Liu Z; Chen S; Guo Y
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.
    Liang H; Xu W; Zhou L; Yang W; Weng J
    Diabet Med; 2017 Jul; 34(7):987-992. PubMed ID: 28321905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
    Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
    PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the SLC47A1 Gene Variant With Responses to Metformin Monotherapy in Drug-naive Patients With Type 2 Diabetes.
    Kim H; Bae S; Yoon HY; Yee J; Gwak HS
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2684-2690. PubMed ID: 35639991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
    Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
    Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
    Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
    Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).
    Joerger M; van Schaik RH; Becker ML; Hayoz S; Pollak M; Cathomas R; Winterhalder R; Gillessen S; Rothermundt C
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):167-72. PubMed ID: 25753371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of metformin.
    Graham GG; Punt J; Arora M; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup LC; Kirkpatrick CM; Ray JE; Timmins P; Williams KM
    Clin Pharmacokinet; 2011 Feb; 50(2):81-98. PubMed ID: 21241070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.